Click on the name to know more
Frequently Asked Questions
Non-selective NSAIDs like Diclofenac and Ketorolac inhibit both COX-1 and COX-2 enzymes, providing effective pain relief but with potential gastrointestinal side effects due to COX-1 inhibition in the stomach lining. COX-2 selective inhibitors like Etoricoxib and Nimesulide preferentially target the COX-2 enzyme responsible for inflammation and pain, offering comparable efficacy with reduced gastric irritation, making them preferable for patients with history of peptic ulcers or GI sensitivity.
Lornoxicam is unique among NSAIDs due to its balanced inhibition of COX-1 and COX-2 with a short elimination half-life, providing rapid onset of analgesia while allowing quick clearance from the body. This makes it particularly suitable for acute pain conditions like renal colic, postoperative pain, and acute musculoskeletal pain where rapid relief is needed without prolonged systemic exposure. Its analgesic potency is comparable to opioids in certain pain models without the associated respiratory depression or addiction risk.
Yes, we can supply pain relief APIs with specifications tailored to different dosage forms. For oral solid dosage manufacturing, APIs are supplied with defined particle size distribution, flow properties, and compressibility parameters suitable for tablet compression or capsule filling. For topical gels and creams, we provide APIs with appropriate solubility profiles and particle size specifications that ensure uniform dispersion in semisolid bases. We work with customers to define the right specification profile for their specific formulation platform.
Each batch of pain relief API undergoes comprehensive pharmacopeial testing including assay potency by HPLC, identification by IR and HPLC retention time, related substances and degradation products profiling, residual solvent analysis by GC, heavy metals content, sulfated ash, loss on drying, specific optical rotation for chiral NSAIDs, and microbial enumeration tests. For specific APIs like Ketorolac and Etodolac, additional chiral purity testing is performed to ensure the correct enantiomeric composition critical for safety and efficacy.
We maintain comprehensive impurity profiles for all our NSAID APIs, tracking identified and unidentified impurities against ICH Q3A thresholds. Forced degradation studies are conducted under acidic, basic, oxidative, photolytic, and thermal stress conditions to characterize the degradation pathway of each API. Batch-to-batch impurity data is monitored using statistical process control to ensure consistency. This data is shared with customers through regulatory documentation packages to support their drug product filings and stability commitments.
